Graphical Abstract: Left: Maximum intensity projection of 68Ga-PSMA PET in a...
Graphical Abstract: Left: Maximum intensity projection of 68Ga-PSMA PET in a patient with newly diagnosed prostate cancer shows intense uptake in the primary prostate lesion and focal uptake in multiple lymph nodes consistent with metastatic disease. Right: Kaplan–Meier curves show that high uptake and presence of metastatic disease on PET are associated with earlier biochemical recurrence.

Image source: SNMMI; Moradi et al., Journal of Nuclear Medicine 2022

News • Nuclear medicine

Prostate cancer: PSMA PET/MRI accurately predicts recurrence risk

In men recently diagnosed with intermediate or high-grade prostate cancer, prostate specific membrane antigen (PSMA) PET/MRI can successfully determine whether their cancer is likely to return within two years of a prostatectomy.

Armed with this information, physicians can identify patients who could benefit from additional treatment and/or frequent surveillance. This research was published in the Journal of Nuclear Medicine

Prostate cancer is known to have very variable behavior and outcomes. While many cases of localized prostate cancer can be treated successfully, some patients experience a rapid progression even after prostatectomy or radiation therapy. Therefore, initial risk stratification is important to determine treatment decisions and subsequent management of prostate cancer patients. “Clinicians currently use biopsy findings and clinical information, such as prostate-specific antigen (PSA) levels, to predict if prostate cancer is slow-growing or if it will spread quickly and require aggressive treatments,” said Andrei Iagaru, MD, professor of Radiology–Nuclear Medicine and chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University Medical Center in Stanford, California. “However, functional imaging, such as PET/MRI, is increasingly being considered as a way to identify patients at risk for persistent or recurrent disease.”

PSMA PET/MRI adds value to the pre-therapy evaluation of patients with newly diagnosed prostate cancer, and the information from PET seems to be as reliable, if not more reliable, than biopsy findings and clinical information

Farshad Moradi

In the study, researchers examined the value of 68Ga-PSMA-11 PET/MRI for risk stratification of newly diagnosed prostate patients prior to initial therapy. Seventy-three patients with a new diagnosis of intermediate- or high-grade prostate cancer were imaged with 68Ga-PSMA-11 PET/MR between April 2016 and December 2020. PET findings were divided into groups based on low versus high uptake in the primary lesion and the presence or absence of metastatic disease. These findings were compared to biopsy results and clinical information. The relationship between the PET/MRI findings and patient outcomes were also examined. 

High uptake in the primary lesion and the presence of PSMA metastasis were associated with biochemical failure or rapid recurrence within two years of prostatectomy. In contrast, patients with low uptake in the primary lesion who did not have evidence of metastatic disease on PET/MRI had a low likelihood of experiencing recurrence during the follow-up period. “PSMA PET/MRI adds value to the pre-therapy evaluation of patients with newly diagnosed prostate cancer, and the information from PET seems to be as reliable, if not more reliable, than biopsy findings and clinical information in predicting which patients will have suboptimal outcome,” stated Farshad Moradi, MD, PhD, clinical associate professor of Radiology–Nuclear Medicine at Stanford University Medical Center in Stanford, California. “This study provides support for including PSMA PET to aid in clinical decision making about prostate cancer therapy options. PSMA pre-surgery may contribute to establishing one of the ‘killer applications’ for PET/MRI.” 


Source: Society of Nuclear Medicine and Molecular Imaging

11.01.2023

Read all latest stories

Related articles

Photo

Article •

PET-CT for radiation therapy planning:

For individualised radiotherapy, high-precision delineation and characterisation of the tumour is critical. If highest radiation doses are delivered in a targeted fashion, the chance of tumour cell…

Photo

News • Nuclear imaging

New PET radiotracer to reduce false-positive cancer findings after Covid-19 vaccination

A novel imaging agent can reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for Covid-19. This may mitigate the issue of tracer uptake in lymph nodes…

Photo

Article • Image augmentation, interpretation and evaluation

AI in multimodality hybrid imaging: a diamond in the rough

AI-based models for multimodality hybrid imaging have the potential to be a potent clinical tool but are currently held back by a lack of transparency and maturity, says Dr Irène Buvat, from the…

Related products

Biograph mMR

PET/MRI

Siemens Healthineers · Biograph mMR

Siemens Healthcare GmbH
Biograph mMR

PET/MR

Siemens Healthineers · Biograph mMR

Siemens Healthcare GmbH
2-part PMMA CT-Phantom

Testing Devices

IBA Dosimetry · 2-part PMMA CT-Phantom

IBA Dosimetry GmbH
3-part PMMA CT-Phantom

Testing Devices

IBA Dosimetry · 3-part PMMA CT-Phantom

IBA Dosimetry GmbH
Accutron CT

Injectors

Medtron AG · Accutron CT

MEDTRON AG
Subscribe to Newsletter